Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I5HE
|
||||
| Former ID |
DPR000082
|
||||
| Drug Name |
NPY5RA-972
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Obesity [ICD9: 278; ICD10:E66] | Preclinical | [1] | ||
| Company |
AstraZeneca
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H25N3O2
|
||||
| Canonical SMILES |
CC1=C(C=CC2=C1C3=CC=CC=C3N2C(C)C)NC(=O)N4CCOCC4
|
||||
| InChI |
1S/C21H25N3O2/c1-14(2)24-18-7-5-4-6-16(18)20-15(3)17(8-9-19(20)24)22-21(25)23-10-12-26-13-11-23/h4-9,14H,10-13H2,1-3H3,(H,22,25)
|
||||
| InChIKey |
ZNFMHLDBJPAFEQ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Neuropeptide Y receptor 5 | Target Info | Antagonist | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.